Finanzen von Arbutus Biopharma Corp (ABUS)ABUSArbutus Biopharma Corp

Evaluating the bottom line, Arbutus Biopharma Corp maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -567.16%, while the net margin is -507.20%. These profitability ratios, combined with a Return on Equity (ROE) of 89.58%, provide a clear picture of how effectively ABUS converts its operational activities into shareholder value.

In the context of the broader market, ABUS competes directly with industry leaders such as AKTS and CGEM. With a market capitalization of $814.21M, it holds a significant position in the sector. When comparing efficiency, ABUS's gross margin of 100.00% stands against AKTS's 100.00% and CGEM's N/A. Such benchmarking helps identify whether Arbutus Biopharma Corp is trading at a premium or discount relative to its financial performance.

In Q1 2026, ABUS reported a significant net income of $169.7 million, a strong turnaround from previous losses, and a gross margin of 100%, indicating strong revenue generation relative to costs.